tbuckley/cabot-search huggingface dataset:
Missing Source Credit for Figure and Table
Authors: Bingshu Chen, Lillian Siu, Wendy Parulekar
Journal: JAMA Oncology (2017)

In Reply Regarding the 2-stage test design, we applied in the CCTG HN.6 study 1 the following stepwise test procedure (Figure 1 by Wang et al 2 ), which controls the overall type I error rate at 5% used to analyze progression-free survival (PFS): 1.In the first step, whether accelerated-fractionation radiotherapy (AFX) plus panitumumab is superior to standardfractionation radiotherapy (SFX) plus cisplatin is tested using a stratified log-rank test.2. If the 2-sided P value of the stratified log-rank test is greater than .05(ie, superiority of AFX plus panitumumab to SFX plus cisplatin is not demonstrated), a test for the noninferiority of AFX plus panitumumab to SFX plus cisplatin is performed that also includes all randomized patients.Noninferiority of AFX plus panitumumab to SFX plus cisplatin is claimed when the upper limit of a 2-sided 95% confidence interval for the hazard ratio of AFX plus panitumumab to SFX plus cisplatin, derived from a stratified Cox model adjusting stratification factors at randomization with a single treatment covariate, is less than or equal to 1.15.Regarding power for the noninferiority test, we agree with Cheng et al that a large number of events (ie, 1650) is needed to have 80% power for noninferiority when 2 arms have the same distribution.However, as stated in the study protocol, when the study was designed, we expected a certain amount of efficacy for the experimental arm (AFX plus panitumumab); therefore, with 246 events observed at the time of final analysis for this study, we would have 80% power to claim noninferiority at a 5% α level if the true hazard ratio of AFX plus panitumumab to SFX plus cisplatin was not higher than 0.81 (which corresponds to a difference not lower than 7.6% in the 2-year PFS between the AFX plus panitumumab arm and the SFX plus cisplatin arm).Regarding that the study was underpowered for both the superiority test and noninferiority test, this limitation has already been discussed in our article.We thank Cheng et al for pointing out the potential use of restricted mean PFS time as an alternative way to test noninferiority.We have calculated the 36-month restricted mean PFS time for AFX plus panitumumab and SFX plus cisplatin as 29.31 and 28.46 months, respectively.The upper bound for the confidence interval for the difference of the 36-month RMST for SFX plus cisplatin vs AFX plus panitumumab was 1.82 months, which is close to the 1.7 months estimated by Cheng et al based on data scanned from Figure 2 of our article, but greater than 5% of 36 months.We will consider the design of clinical trials with this methodology in the future.
MEDICAL ETHICS
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentary
Authors: Ioannis S. Papanikolaou
Journal: Endoscopy (2021)

Colovesical fistula is a well-known complication of pelvic radiation, especially when the latter is combined with surgery [1]. Interventional management is usually necessary but difficult, with surgery preferably avoided as these patients are poor surgical candidates and the irradiated field is an unfriendly surgical environment [1] [2]. In this e-Video, the authors elegantly demonstrate how a patient with sepsis due to a fistula between a neobladder and the rectum was successfully treated with placement of an atrial septal defect closure device. These devices have been used for treatment of tracheoesophageal fistulas [3] but seem to be effective in the lower gastrointestinal (GI) tract as well. Among the highlights of the case, one should point out the interdisciplinary approach, with co-operation between GI endoscopists and urologists for effective device placement, and the trend of modern GI endoscopy to expand into spaces adjacent to but outside of the GI tract.
From the Institute of Medicine
Authors: A. M. Pope
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DISEASES OF ITALIAN EAST AFRICA
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fatal diphenylhydantoin poisoning. A case report
Authors: F. A. Laubscher
Journal: JAMA (1966)

DIPHENYLHYDANTOIN is a synthetic compound which has been widely used for more than 25 years as one of the safest anticonvulsant drugs. Fatalities resulting either from untoward reactions with usual doses or from overdoses of the drug are very rare. Search of the literature indicates that only one case has been previously reported in which the fatality occurred from diphenylhydantoin intoxication and resulting central nervous system depression.<sup>1</sup> The minor symptoms of acute diphenylhydantoin intoxication include dizziness, tremors, and visual disturbances such as diplopia or mydriasis. More severe symptoms include vomiting, difficulty in swallowing, respiratory distress, fatigue, insomnia, irritability, ataxia, confusion, and hallucinations and delusions.<sup>2</sup>There are reports of adults ingesting 4.5, 8.3, and 21.5 gm who subsequently had severe central nervous system depression but eventually recovered.<sup>3,4</sup>Renal dialysis was used in two of these patients. Ingestion of as much as 900 mg by a child 2 years
NEXT-GENERATION SEQUENCING-BASED CLONALITY ASSESSMENT OF IMMUNOGLOBULIN GENE REARRANGEMENTS DISTINGUISHES RELAPSE FROM SECOND PRIMARY CLASSICAL HODGKIN LYMPHOMA
Authors: D. van Bladel, M. van den Brand, J. Rijntjes, A. Brinkman, T. Reigl, N. Darzentas, C. Hess, K. Hebeda, P. Groenen, H. van Krieken, B. Scheijen
Journal: HemaSphere (2019)
Food allergy
Authors: H. A. Sampson
Journal: JAMA (1987)

FOOD allergy is widely perceived by the public as a major health problem.<sup>1</sup>Although the true prevalence of food allergy is unknown, it is probably much less common than thought. Its prevalence among children has been variously estimated from 0.3% to 7.5%,<sup>2</sup>and it is believed that the incidence decreases with age. Acute allergic reactions to foods that are clearly IgE mediated can, however, develop in adults who previously tolerated foods with impunity.<sup>3,4</sup>Clinically, food-induced reactions of the immediate-hypersensitivity type are well documented and include urticaria, angioedema, and anaphylaxis. Reactions to foods mediated through antigen-antibody—complex and delayed-hypersensitivity mechanisms remain to be implicated, except in gluten-induced enteropathy and severe milk- and soyinduced gastroenteropathies in infants and children.<sup>5</sup> <h3>CLINICAL FEATURES</h3> Immunologically mediated reactions to foods are expressed clinically by a diversity of signs and symptoms, ranging from abdominal pain to generalized anaphylaxis. These clinical expressions of food allergy
Agranulocytosis associated with gentamicin
Authors: J. C. Chang
Journal: JAMA (1975)

GENTAMICIN is an aminoglycoside antibiotic derived from<i>Micromonospora purpurea</i>. It has broadspectrum antibacterial action against most strains of<i>Staphylococcus, Escherichia, Enterobacter</i>, and<i>Pseudomonas</i>,<sup>1</sup>and has been widely used in clinical practice with satisfactory results. However, like many other antibiotics, it is not without side-effects. The more frequently reported adverse reactions are nephrotoxicity, neurotoxicity, and allergic skin reactions.<sup>2</sup> No serious hematologic complications have been recorded although transient granulocytopenia has been observed.<sup>3,4</sup>We recently encountered a patient who had agranulocytosis associated with gentamicin and who recovered without any serious incident. <h3>Report of a Case</h3> A 68-year-old man was admitted to the Veterans Administration Hospital, Dayton, on May 6, 1974, with chief complaints of shortness of breath and chronic cough from an acute exacerbation of chronic obstructive lung disease. On admission, the patient was emaciated, appeared chronically ill, and was in moderate respiratory distress. Vital signs included a temperature of
Acute acalculous cholecystitis caused by Salmonella indiana
Authors: C. W. Campbell
Journal: JAMA (1975)

<i>SALMONELLA</i>have long been known to cause a chronic carrier state, especially in association with gallbladder disease. In such cases, cholecystectomy is a well-established procedure, although it fails in 25% to 35%.<sup>1</sup>Acute cholecystitis associated with nontyphosa<i>Salmonella</i>infection is unusual. Its occurrence without cholelithiasis is rare. Bonta and Lovinggood<sup>2</sup>reported one case caused by<i>S oranienberg</i>in a child and another, with<i>S paratyphi</i>, was reported by Main.<sup>3</sup>We describe a third. <h3>Report of a Case</h3> A 33-year-old tavern owner sought medical advice because of aching abdominal pain and soreness in the right upper quadrant for three days. The pain was abrupt in onset, with associated right-shoulder discomfort, nausea, and anorexia. By the time of his examination the pain had subsided, but soreness persisted. His medical history was unremarkable except for a similar episode with fever and jaundice, which had prompted a brief hospitalization in another
PLACEMENT ASSISTANCE ON RELEASE FROM MILITARY SERVICE
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review Neoplastic Disease . Third Edition. A treatise on Tumors. By James Ewing, M.D., Sc.D., Professor of Pathology at Cornell University Medical College, New York City, Third Edition, Revised and Enlarged. Octavo of 1127 pages with 546 illustrations. Published by W. B. Saunders Company, Philadelphia and London.
Journal: New England Journal of Medicine (1928)
Radiology Quiz
Authors: Barry Kelly, Ian C Bickle
Journal: BMJ (2001)

A 32 year old sports teacher presented via her puzzled general practitioner complaining of a gradual progression of shortness of breath when exerting herself at work. She also had an annoying cough and was uncharacteristically tired. Her only other complaint was of a sore red right eye that kept watering. On examination a small, non-tender lump was noted in the right supraclavicular fossa. A chest radiograph shown here was taken.
The Duty to Attend Upon the Sick-Reply
Authors: Oscar W. Clarke
Journal: JAMA (1992)

<h3>In Reply.</h3> —Dr Passey's letter raises several points. The first seems to be that refusing to treat patients with HIV constitutes a "meaningful choice" that should be highly valued. What remains unclear is why preservation of an option that both disserves patients and fails to maintain professional standards should be applauded under the rubric of "freedom of choice." Second, although we share many of Dr Passey's concerns about the growing regulation of the medical profession, we do not believe that licensing boards' support of ethical standards degrades the profession. The concerns we might have when government regulates with an eye toward economics rather than patient welfare are not present here where the medical profession itself is setting the standards. This is simply not a situation where the government is at odds with professional and ethical standards; they are in full congruity. Moreover, one need not espouse "a state monopoly on
High-Dose Chemotherapy With Autologous Bone Marrow Transplantation for the Treatment of Metastatic Breast Cancer
Authors: David M. Eddy
Journal: Journal of Clinical Oncology (1992)

Tables 1 to 4 contained errors in the report "High-Dose Chemotherapy With Autologous Bone Marrow Transplantation for the Treatment of Metastatic Breast Cancer" by Eddy (J Clin Oncol 10:657–670, 1992). They are reprinted here correctly in their entirety: Please see the PDF for Table.
Abstract 18980: Improving Anticoagulation Knowledge and Quality of Life in Older Adults Using Tablet Mobile Applications
Authors: Jung-Ah Lee, Alpesh N Amin
Journal: Circulation (2015)

Background: Older adults with cardiovascular diseases who require oral anticoagulation therapy (AT) report difficulty managing medications and diet, which affects therapeutic benefit and quality of life (QOL). Mobile health (mHealth) tools such as health applications (app) via smartphones or tablets can assist in managing AT but such tools have not been tested among older adults including Spanish speaking elders. Objective: The objective of the study was to test the feasibility of an mHealth intervention composed of culturally appropriate and age-sensitive components to improve QOL in older adults on AT. Methods: The pilot study used a single-arm, experimental, pre-post design to assess the feasibility of a 12-week mHealth-based intervention in older adults with AT by examining changes in outcomes (ie, knowledge, adherence, QOL, perception, depression) and usability of the warfarin app on a 10-inch tablet computer after 3-month use. Results: Twenty older patients from two anticoagulation clinics have enrolled in the study - average age 67.7 ± 9.8 years; predominantly male (14/20, 70%); Caucasians (9/20, 45%), Hispanics (8/20, 40%); high school completion (13/20, 65%); living with family (16/20, 80%); average number of comorbidity 3.4 (±1.4). Fifteen participants completed 3-month follow-ups; two dropped due to inability to use the app; one died; two are currently on use of the app. Outcomes were improved from baseline to 3 months (see Table). The mean satisfaction with and mean usefulness of the app were 5.4 of 7 (±1.5) and 5.4 of 7 (±1.4) in usability survey after 3 months. Conclusions: Our findings suggest that on-going mHealth intervention for older adults with chronic diseases show promise in being able to enhance anticoagulation knowledge and QOL with the treatment. The satisfaction of mHealth intervention using the health app was moderate to high in this sample. The findings can be used to modify the health app to make the mHealth intervention more elder-friendly.
Closed Cervical Cranial Trauma Associated with Involvement of Carotid and Vertebral Arteries
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Adverse Ocular Reactions Following Transfusions—United States, 1997-1998
Journal: JAMA (1998)

On December 23, 1997, the Portland region of the American Red Cross (ARC) notified the Oregon Health Division about a cluster of adverse ocular reactions among six patients who had received out-patient red blood cell (RBC) transfusions at a hospital in Washington; all patients experienced severe bilateral conjunctival erythema within 24 hours of transfusion. Since the initial report, 106 similar reactions in 74 patients in 14 states (Alabama, California, Connecticut, Maine, Michigan, Minnesota, Montana, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Washington, and Wisconsin) have been identified. This report summarizes the preliminary findings from three of these states about the ongoing investigation of these reactions.
American Journal of Ophthalmology, Chicago
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Etretinate therapy improves psoriasis but elevates serum lipids
Authors: V. S. Cowart
Journal: JAMA (1982)

A University of Michigan Medical School group has reported success in treating a case of life-threatening psoriasis with a combination of methotrexate and the investigational drug etretinate. However, they also report that etretinate results in an increase in serum triglyceride and cholesterol levels. This increase is important enough and persists long enough that in the view of Charles N. Ellis, MD, assistant professor of dermatology, long-term treatment with etretinate will be a cause for concern unless normalization of lipid levels occurs either spontaneously or can be achieved with medical intervention. The report on the combination therapy was presented at the National Clinical Dermatology Conference in Chicago by Evelyn E. Vanderveen, MD, a dermatology resident. Two major points of interest, she said, are that the combination of drugs did not produce any short-term adverse side effects and that etretinate alone did not control psoriatic arthritis in the patient, a 51-year-old man.